Related Papers
White matter lesions and changes in cerebral microstructure in late-onset major depression: A diffusion tensor imaging study
2008 •
Poul Videbech
Preventing and treating olanzapine-induced obesity with betahistine: a chronic animal model study
2012 •
Nagesh Pai
Australian and New Zealand Journal of Psychiatry
Early age of onset is associated with high rates of anxiety comorbidity in bipolar I and schizoaffective disorder
2008 •
katarina kelin
Schizophrenia Research
Improving somatic health of outpatients with severe mental illness
2014 •
Marian Oud
Background: Patients with severe mental illness (SMI) experience a 13-to 30-year reduction in life expectancy compared with the general population. The majority of these deaths can be attributed to somatic health problems. The risk on somatic health problems is partly increased due to a reduced ability to request care and the fact that the current health care organisation is unable to fulfil the needs of these patients. Our previous work shows that a health check intervention can bypass the inability to request help of patients with SMI by detecting somatic health problems that were not detected previously [1]. The aim of this research project is to develop a policy recommendation on how to improve physical health based on consensus by the major stakeholders: patients, family carers, general practitioners, and mental health care staff. Methods: We used a three round Delphi method. The first round consisted of an inventory of potential policy recommendations, in two consecutive round...
Sedative Properties of Calliandra Portoricensis Root Extracts
1998 •
Peter Akah
The International Journal of Neuropsychopharmacology
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence
2007 •
Kareem Ghalib
Consortium Psychiatricum
Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
2020 •
Alexey Pavlichenko
Background. Cariprazine is a new piperazine derivative atypical antipsychotic, like aripiprazole and brexpiprazole. It has been approved for treating schizophrenia in many countries and has recently been included on the List of Essential Medicines in Russia. Unlike most other atypical antipsychotics, it shows high in vivo occupancy of dopamine D2 and D3 receptors at clinically relevant doses. In animal models, cariprazine has demonstrated dopamine D3 receptor- dependent pro-cognitive and anti-anhedonic effects, suggesting its potential for treating negative symptoms. This review summarizes the efficacy of cariprazine in the treatment of negative symptoms of schizophrenia. Methods. A literature search of databases covering international and Russian journals, for articles published between 1st January 2010 and 1stJune 2020. Results. Cariprazine demonstrated at least comparable efficacy in the treatment of schizophrenia symptoms to active comparators including risperidone, olanzapine o...
Frontiers in Psychiatry
Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
Pavel Mohr
Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmaco*kinetics, drug interactions, or safety and tolerability. The antipsychotic efficacy of all three drugs was established in several placebo-controlled randomized trials (RCTs) in schizophrenia, both acute phase and relapse prevention. In addition, each of the DRPA agents has been tested in other psychiatric disorders, including bipolar disorder or major depression. However, a few studies have examined their comparative clinical efficacy. There are no head-to-head comparisons between aripiprazole, brexpiprazole, or cariprazine. In two acute schizophrenia RCTs of cariprazine and brexpiprazole, aripiprazole was used as an indirect comparator to control for study sensitivity. To assess potential differences in the efficacy of DRPAs, we reviewed data from contro...
Expert Opinion on Drug Discovery
The preclinical discovery and development of cariprazine for the treatment of schizophrenia
2018 •
Marcin Kołaczkowski
Synapse
Involvement of 5‐HT2A receptor and α2‐adrenoceptor blockade in the asenapine‐induced elevation of prefrontal cortical monoamine outflow
2012 •
Monica Marcus
The psychotropic drug asenapine is approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. Asenapine exhibits higher affinity for several 5‐HT receptors and α2‐adrenoceptors than for D2 receptors. Noteworthy, blockage of both the 5‐HT2A and α2‐adrenergic receptors has been shown to enhance prefrontal dopamine release induced by D2 receptor antagonists. Previous results show that asenapine, both systemically and locally, increases dopamine, noradrenaline, and serotonin release in the medial prefrontal cortex (mPFC), and that the increased dopamine release largely depends on an intracortical action. Using reverse microdialysis in freely moving rats, we here assessed the potency of low concentrations of asenapine to cause a pharmacologically significant blockage in vivo of 5‐HT2A receptors and α2‐adrenoceptors within the mPFC, and thus its ability to affect cortical monoamine release by these receptors. Intracortical administration of...
